BRPI1013152A2 - composto que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais. - Google Patents

composto que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais.

Info

Publication number
BRPI1013152A2
BRPI1013152A2 BRPI1013152A BRPI1013152A BRPI1013152A2 BR PI1013152 A2 BRPI1013152 A2 BR PI1013152A2 BR PI1013152 A BRPI1013152 A BR PI1013152A BR PI1013152 A BRPI1013152 A BR PI1013152A BR PI1013152 A2 BRPI1013152 A2 BR PI1013152A2
Authority
BR
Brazil
Prior art keywords
activity
muscle
urethal
sphincters
destructive
Prior art date
Application number
BRPI1013152A
Other languages
English (en)
Inventor
Akihiro Kinoshita
Hidekazu Matsuya
Hiroki Okada
Kazuyuki Ohmoto
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BRPI1013152A2 publication Critical patent/BRPI1013152A2/pt
Publication of BRPI1013152B1 publication Critical patent/BRPI1013152B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26Radicals substituted by sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1013152-3A 2009-06-10 2010-06-09 Composto, composição farmacêutica e medicamento que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais BRPI1013152B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009139657 2009-06-10
JP2009-139657 2009-06-10
JP2009-256008 2009-11-09
JP2009256008 2009-11-09
PCT/JP2010/059771 WO2010143661A1 (ja) 2009-06-10 2010-06-09 膀胱排尿筋収縮および尿道括約筋弛緩作用を有する化合物

Publications (2)

Publication Number Publication Date
BRPI1013152A2 true BRPI1013152A2 (pt) 2016-04-05
BRPI1013152B1 BRPI1013152B1 (pt) 2019-06-18

Family

ID=43308916

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013152-3A BRPI1013152B1 (pt) 2009-06-10 2010-06-09 Composto, composição farmacêutica e medicamento que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais

Country Status (19)

Country Link
US (3) US8410281B2 (pt)
EP (1) EP2441760B1 (pt)
JP (1) JP4807478B2 (pt)
KR (1) KR101633149B1 (pt)
CN (1) CN102803239B (pt)
AU (1) AU2010259585B2 (pt)
BR (1) BRPI1013152B1 (pt)
CA (1) CA2764782C (pt)
DK (1) DK2441760T3 (pt)
ES (1) ES2444500T3 (pt)
IL (1) IL216856A0 (pt)
MX (1) MX2011013283A (pt)
NZ (1) NZ596960A (pt)
PL (1) PL2441760T3 (pt)
PT (1) PT2441760E (pt)
RU (1) RU2531350C2 (pt)
TW (1) TWI437987B (pt)
WO (1) WO2010143661A1 (pt)
ZA (1) ZA201109103B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1013152B1 (pt) * 2009-06-10 2019-06-18 Ono Pharmaceutical Co., Ltd. Composto, composição farmacêutica e medicamento que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais
AU2013309872B2 (en) 2012-08-31 2017-09-14 Ono Pharmaceutical Co., Ltd. Amine salt and crystals thereof
CA2918245C (en) 2013-08-01 2022-08-30 Dignify Therapeutics, Inc. Compositions and methods for inducing urinary voiding and defecation
JP2017533227A (ja) * 2014-11-03 2017-11-09 ウィリアム・ボーモント・ホスピタルWilliam Beaumont Hospital 低活動膀胱症候群を治療するための方法
AR117551A1 (es) 2018-12-31 2021-08-11 Adama Makhteshim Ltd Síntesis de 1,1,2-trifluoro-4-(sulfonil sustituido)-but-1-eno
MX2022001388A (es) * 2019-08-04 2022-03-25 Yeda Res & Dev Proceso para la preparacion de fluensulfona.
CN119039235B (zh) * 2024-08-20 2025-12-16 湖北省医药工业研究院有限公司 合成阿伐那非、中间体的方法及用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (pt) 1970-06-10 1975-02-04
JPS5231404B1 (pt) 1971-04-28 1977-08-15
JPS57156460A (en) 1981-03-20 1982-09-27 Ono Pharmaceut Co Ltd Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation
JPS60197667A (ja) 1984-03-19 1985-10-07 Ono Pharmaceut Co Ltd 6―ケト―プロスタグランジン類似化合物及びその製造方法
KR20000070903A (ko) 1997-02-10 2000-11-25 오노 야꾸힝 고교 가부시키가이샤 11,15-o-디알킬프로스타글란딘 e 유도체, 이것의 제조 방법 및 이것을 유효 성분으로 함유하는 약제
JPH11130678A (ja) 1997-08-27 1999-05-18 Kaken Pharmaceut Co Ltd 神経圧迫による神経障害改善剤
IL159996A0 (en) 2001-07-23 2004-06-20 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
JP2005053707A (ja) 2001-07-30 2005-03-03 Kankyo Device Kenkyusho:Kk 可視光応答性材料の製造方法
JP4547912B2 (ja) 2002-03-05 2010-09-22 小野薬品工業株式会社 8−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
US7551916B2 (en) 2002-07-11 2009-06-23 Nokia Corporation Method and device for automatically changing a digital content on a mobile device according to sensor data
JP4582456B2 (ja) 2003-01-21 2010-11-17 小野薬品工業株式会社 8−アザプロスタグランジン誘導体およびその医薬用途
US20070167403A1 (en) 2003-04-03 2007-07-19 Yoshifumi Takenobu Remedy for spinal canal stenosis
US7833995B2 (en) 2003-12-05 2010-11-16 Ono Pharmaceutical Co., Ltd. Blood flow promoters for cauda equina tissues
JPWO2005061492A1 (ja) 2003-12-22 2007-07-12 小野薬品工業株式会社 含窒素複素環化合物およびそれらを有効成分とする薬剤
WO2006016689A1 (ja) 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤
JP4893999B2 (ja) 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
JP2006129788A (ja) 2004-11-05 2006-05-25 Nippon Starch Chemical Co Ltd 揚げ物用ミックス
CA2610692C (en) * 2005-06-03 2014-11-25 Ono Pharmaceutical Co., Ltd. Ep2 agonists which may have an ep3 agonistic effect for regeneration and/or protection of nerves
JP5630264B2 (ja) * 2008-06-06 2014-11-26 小野薬品工業株式会社 膀胱排尿筋収縮および尿道括約筋弛緩剤
BRPI1013152B1 (pt) * 2009-06-10 2019-06-18 Ono Pharmaceutical Co., Ltd. Composto, composição farmacêutica e medicamento que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais

Also Published As

Publication number Publication date
AU2010259585A1 (en) 2012-01-19
EP2441760A1 (en) 2012-04-18
ZA201109103B (en) 2012-08-29
US20130184236A1 (en) 2013-07-18
BRPI1013152B1 (pt) 2019-06-18
JP4807478B2 (ja) 2011-11-02
HK1169117A1 (en) 2013-01-18
US8716490B2 (en) 2014-05-06
PT2441760E (pt) 2014-01-07
TWI437987B (zh) 2014-05-21
RU2531350C2 (ru) 2014-10-20
EP2441760B1 (en) 2013-11-20
WO2010143661A1 (ja) 2010-12-16
US8410281B2 (en) 2013-04-02
IL216856A0 (en) 2012-03-01
JPWO2010143661A1 (ja) 2012-11-29
US9150528B2 (en) 2015-10-06
AU2010259585B2 (en) 2015-11-19
US20120088805A1 (en) 2012-04-12
CN102803239A (zh) 2012-11-28
MX2011013283A (es) 2012-01-12
KR101633149B1 (ko) 2016-06-23
NZ596960A (en) 2013-04-26
PL2441760T3 (pl) 2014-05-30
TW201103539A (en) 2011-02-01
DK2441760T3 (en) 2014-02-17
CA2764782C (en) 2017-07-25
CN102803239B (zh) 2015-04-15
EP2441760A4 (en) 2012-12-05
ES2444500T3 (es) 2014-02-25
CA2764782A1 (en) 2010-12-16
KR20120026088A (ko) 2012-03-16
US20140171387A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
SMT201600273B (it) Genz 112638 per trattare la malattia di gaucher o fabry in terapia di combinazione
BRPI0908030A2 (pt) Corpo roscado de extremidade dupla e corpo internamente roscado
EP2513023A4 (en) COMPOSITIONS OF CIS-1,1,1,4,4,4-HEXAFLUOR-2-BUTENE AND ITS USES
BRPI1013152A2 (pt) composto que tem atividade de contração muscular destrusora e atividade muscular relaxante dos esfincteres uretais.
BR112013013402A2 (pt) combinações de ingredientes ativos que compreendem piridiletilbenzamidas e outros ingredientes ativos
BRPI1013503A2 (pt) formulação de iniciador não cromado que inibe corrosão, e, estrutura
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
AP2013006984A0 (en) BicycloÄ3.2.1Üoctyl amide derivatives and uses of same
EP2432492A4 (en) APPLICATION AND USE OF PRG4 AND THERAPEUTIC MODULATION THEREOF
IT1403381B1 (it) Braccio trasversale e procedimento per la realizzazione di un braccio trasversale.
ZA201100560B (en) Pest-control compositions and methods having high target and low non-target activity
ZA201301231B (en) Treatment of l-dopa,dopamine agonist and/or dopamine enhancer induced disorders
GB2497453B (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
EP2393836A4 (en) SAM-6 VARIANTS, TARGET AND METHODS OF USING SAME
PL388575A1 (pl) Nowy 7-O-β -D-4'''metoksyglukopiranozyd 8-prenylonaringeniny i sposób jego wytwarzania
BR112012003026A2 (pt) formulações e métodos de emprego de desinfetante anidro.
FR2927632B1 (fr) Cornee et muqueuse reconstruites.
IT1397183B1 (it) Dispositivo e procedimento per definire la posizione di un oggetto
BRPI0922581A2 (pt) pateamento de arame de aço em estanho e o arame de aço daí resultante.
PL388612A1 (pl) Nowa 7-O-n-pentylo-8-prenylonaringenina oraz sposób jej otrzymywania
BR112012018072A2 (pt) formulação anidra, método e utilização da formulação
Fields The psychology of pain
ES1071894Y (es) Protector muscular
PL2654752T3 (pl) Pochodne diarylopirydazynonów, ich wytwarzanie, i ich zastosowanie do leczenia ludzi
IT1398845B1 (it) Composizione per la prevenzione e/o il trattamento della fatica muscolare

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/06/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/06/2010, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2778 DE 02-04-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.